Back to today’s briefing

Story perspectives

Beam Therapeutics Revolutionizes Gene Editing for Genetic Disorders

3/15/2025

27 5

Summary

Story summary

Beam Therapeutics has made a groundbreaking leap in gene editing, successfully correcting genetic mutations in patients with alpha-1 antitrypsin deficiency (AATD) through their innovative BEAM-302 therapy. This cutting-edge method preserves DNA structure, leading to remarkable increases in protein levels and safety during clinical trials, paving the way for transformative treatments for numerous genetic disorders.

1 of 1

Story summary

Beam Therapeutics has made a groundbreaking leap in gene editing, successfully correcting genetic mutations in patients with alpha-1 antitrypsin deficiency (AATD) through their innovative BEAM-302 therapy. This cutting-edge method preserves DNA structure, leading to remarkable increases in protein levels and safety during clinical trials, paving the way for transformative treatments for numerous genetic disorders.